Drug profile · INN
ofatumumab
KESIMPTA
ofatumumab (KESIMPTA) is a b-lymphocyte antigen cd20 binding agent. Associated with Novartis Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
Drug details — ofatumumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 8
- Data quality
- 0.84
Quick answer
ofatumumab (KESIMPTA) is a b-lymphocyte antigen cd20 binding agent. Associated with Novartis Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
B-lymphocyte antigen CD20 binding agent
Primary target: B-lymphocyte antigen CD20
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ofatumumab?
ofatumumab (KESIMPTA) is a b-lymphocyte antigen cd20 binding agent. Associated with Novartis Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ofatumumab?
KESIMPTA is a marketed brand name for ofatumumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ofatumumab?
ofatumumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.